Learning from DSP107, a CD47x4-1BB bi-specific, to Advance Therapies into the Future & Consider the Continued Therapeutic Potential of CD47
Time: 11:30 am
day: Conference Day One
Details:
- Improving target specificity and activity using bi-specific fusion protein
- Transforming safety profile and avoiding hematological toxicities
- Enhancing the treatment potential of solid and hematological malignancies
